Volume : 11, Issue : 02, February – 2024
Title:
OVERVIEW OF ANTI-NEOPLASTIC: CANCER
Authors :
Payal Ramesh Gaikwad, Sanjana Shridhar Walwante, Kalyani Naresh Sadafale, Vinayak Katekar , Dr. Swati Deshmukh
Abstract :
Use of computational techniques has accelerated the discovery process. Traditional drug discovery process was laborious, time consuming and was expensive. The success rate was also very low. In the modern drug discovery process the use of computational techniques has made the drug discovery fast and cost effective with higher success rates. The present review highlights the various computational techniques used in the drug discovery, their advantages and limitations.
Cite This Article:
Please cite this article in press Payal Ramesh Gaikwad et al., Overview Of Anti-Neoplastic: Cancer , Indo Am. J. P. Sci, 2024; 11 (02).
Number of Downloads : 10
References:
1. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-8653.
2. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275-292.
3. Chabner BA, Roberts TG Jr. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65-72.
4. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(11):2643-2655.
5. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):
6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.
7. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734
8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
9. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
10.Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212-220.
11. [22/01, 21:28] : 11.Exposure of family members to antineoplastic drugs via excreta of treated cancer patients
Michiko Yuki et al. J Oncol Pharm Pract. 2013 Sep.
12. [22/01, 21:30] : 12.Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy Edgar Pérez-Herrero et al. Eur J Pharm Biopharm. 2015 Jun.
13.[22/01, 21:31] : 13.Analysis of anticancer drugs: a review Susanne Nussbaumer et al. Talanta. 2011.
15;85(5):2265-89. Doi: 10.1016/j.talanta.2011.08.034. Epub 2011 Aug 24.
14. [22/01, 21:32] : 14.Clinical pharmacology of anticancer agents in relation to formulations and administration routes J M Terwogt et al. Cancer Treat Rev. 1999 Apr. Cancer Treat Rev . 1999 Apr;25(2):83-101. Doi: 10.1053/ctrv.1998.0107.
15.[22/01, 21:38] : 15.Antineoplastic drug residues inside homes of chemotherapy patients
Antje Böhlandt et al. Int J Hyg Environ Health. 2017 Jun. Int J Hyg Environ Health . 2017 Jun;220(4):757-765. Doi: 10.1016/j.ijheh.2017.03.005. Epub 2017 Mar 27.
16.[22/01, 21:38] : 15.Antineoplastic drug residues inside homes of chemotherapy patients
Antje Böhlandt et al. Int J Hyg Environ Health. 2017 Jun.Int J Hyg Environ Health . 2017 Jun;220(4):757-765.
Doi: 10.1016/j.ijheh.2017.03.005. Epub 2017 Mar 27.
17. [23/01, 18:51] : A Systematic Review of Adherence to Oral Antineoplastic Therapies
Joseph A. Greer,corresponding authora Nicole Amoyal,a Lauren Nisotel,a Joel N. Fishbein,a James MacDonald,a Jamie Stagl,a Inga Lennes,a Jennifer S. Temel,a Steven A. Safren,b and William F. Pirla
18. [23/01, 18:52] : Oncologist. 2016 Mar; 21(3): 354–376. Published online 2016 Feb 26. Doi: 10.1634/theoncologist.2015-0405 PMCID: PMC4786357PMID: 26921292 [23/01, 19:27] :
19.History of Anticancer Drugs Science & Society
View previous versionsGraham B Jones
First published: 15 October 2014 [23/01, 19:32] : Drugs Drugs. 2015; 75: 1993–2016. Published online 2015 Oct 26. Doi: 10.1007/s40265-015-0489-4
PMCID: PMC4642600PMID: 26501980
20. [23/01, 19:33] : Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Matthew Trendowski
21..[23/01, 23:17] : Antineoplastic Drugs
Karl K. Kwok, … James N. Gibson, in Pharmacology and Therapeutics for Dentistry (Seventh Edition), 2017
[23/01, 23:41] :
22. Geriatr Rehabil. Author manuscript; available in PMC 2020 Jan 1.Published in final edited form as:Top Geriatr Rehabil. 2019 Jan-Mar; 35(1): 15–30. Doi: 10.1097/TGR.0000000000000212
PMCID: PMC6474376NIHMSID: NIHMS1506660PMID: 31011239